Since it was first reported on 31st December 2019 in Wuhan, China, the Coronavirus disease (COVID-19) outbreak has gone global. Classified as a “high risk” threat globally by the World Health Organization (WHO), COVID-19 has infected 75,748 globally and caused 2,129 deaths worldwide, virtually shutting down China, one of the largest engines of the global economy -- and the effect on global trade is beginning to show. Indian exporters, particularly in the seafood sector, have been hit particularly hard, and now FIEO has warned that the pain might spread to other sectors too as the global supply chain gets disrupted. Pharma, in particular, has faced a lot of scrutinies, with the government banning exports of several drugs and medical equipment to prioritize them for domestic consumption. However, industry stakeholders, such as Biocon’s Kiran Mazumdar Shaw, feel that the ban will do more harm than good, and that trade should be allowed to continue alongside domestic stockpiling. As fear and uncertainty spread in the coming weeks, the government needs to ensure it is safeguarding Indian trade as well as the health and safety of its citizens. Meanwhile, US President Donald Trump is scheduled to arrive in India for a two-day visit on 24th and 25th February. This is Trump’s first official visit as President and it comes at a particularly tumultuous time in the bilateral relationship. While Trump and Indian Prime Minister Narendra Modi share a good personal relationship, the US President has publicly stated he’s “saving a big trade deal with India for later”. It remains to be seen whether the bilateral trade between the two nations will receive a shot in the arm from Trump’s visit, or not.